Compare POWI & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POWI | OGN |
|---|---|---|
| Founded | 1988 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 1997 | 2020 |
| Metric | POWI | OGN |
|---|---|---|
| Price | $46.97 | $6.91 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 4 |
| Target Price | ★ $61.00 | $11.75 |
| AVG Volume (30 Days) | 870.8K | ★ 4.2M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | ★ 1.79% | 1.16% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.39 | ★ 0.72 |
| Revenue | $443,504,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $8.12 | $0.42 |
| Revenue Next Year | $16.54 | $1.67 |
| P/E Ratio | $123.96 | ★ $9.60 |
| Revenue Growth | ★ 5.86 | N/A |
| 52 Week Low | $30.86 | $6.18 |
| 52 Week High | $63.04 | $15.88 |
| Indicator | POWI | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 52.71 | 36.47 |
| Support Level | $44.13 | $6.48 |
| Resistance Level | $49.03 | $7.74 |
| Average True Range (ATR) | 2.08 | 0.37 |
| MACD | -0.10 | -0.08 |
| Stochastic Oscillator | 35.83 | 23.28 |
Power Integrations Inc designs, develops, and markets analog and mixed-signal integrated circuits (ICs) and other electronic components and circuitry used in high-voltage power conversion. Products are used in power converters that convert electricity from a high-voltage source to the type of power required for a specified downstream use. Products are used in electronic products including mobile phones, computing and networking equipment, appliances, electronic utility meters, battery-powered tools, industrial controls, home automation, or Internet of Things applications such as networked thermostats, power strips, and security devices. Geographically, the company generates maximum revenue from China and Hong Kong.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.